Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?

Dal, Fatih; Ökmen, Hasan; Ulusan, Kıvılcım; Çolak, Şükrü; Havare, Semiha Battal; Trabulus, Didem Can; Ferlengez, Ekrem; Sarı, Serkan

doi:10.1590/1806-9282.20211168

Cited by 3 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It remains unclear whether the multiple foci of MF/MC breast cancers develop simultaneously and independently or whether they originate from one primary tumor. 20,22,23,25,[27][28][29] A subsequent question then arises: whether the cancer cells from these foci are heterogeneous or homogeneous. Therefore, many studies have investigated the similarities and differences between these multiple, synchronous tumors in terms of tumor grades, histological and molecular subtypes.…”

Section: Heterogeneity Among Multiple Tumors In Multifocal/multicentr...mentioning

confidence: 99%

“…Because few studies report homogeneity, for ease of discussion, we have converted the homogeneity results into heterogeneity ( 21,24 Regarding histological subtypes, a wide range of heterogeneity was found among foci: 7.9%-37.5%. 20,22,24,26,27,42 In addition, Dal et al reported 15.7% heterogeneity within the largest foci. 27 Regarding molecular subtypes, about 8.0%-10.1% of MF/MC patients exhibited heterogeneity across different foci.…”

Section: Heterogeneity Among Multiple Tumors In Multifocal/multicentr...mentioning

confidence: 99%

“…20,22,24,26,27,42 In addition, Dal et al reported 15.7% heterogeneity within the largest foci. 27 Regarding molecular subtypes, about 8.0%-10.1% of MF/MC patients exhibited heterogeneity across different foci. 22,27 Various research groups compared the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) between individual foci in MF/MC breast cancer patients.…”

Section: Heterogeneity Among Multiple Tumors In Multifocal/multicentr...mentioning

confidence: 99%

“…27 Regarding molecular subtypes, about 8.0%-10.1% of MF/MC patients exhibited heterogeneity across different foci. 22,27 Various research groups compared the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) between individual foci in MF/MC breast cancer patients. The heterogeneity of ER, PR, and HER2 ranged from 0.0% to 18.0%, 6.0% to 11.1%, and 0.0% to 6.0%, respectively.…”

Section: Heterogeneity Among Multiple Tumors In Multifocal/multicentr...mentioning

confidence: 99%

“…heterogeneity of their grades, histological types, molecular subtypes, and genetic profiles and the impact of these features on the tumors' aggressiveness and patient prognosis. [20][21][22][23][24][25][26][27][28] Other studies have investigated the effects of MF/MC subtypes on the expression of molecular biomarkers, genes of canonical cancer pathways, and cancer stem cell biomarkers. 8,25,27,[29][30][31][32][33][34] In this paper, we aim to review and update the current understanding of MF/MC breast cancers in terms of definitions, incidence, prognosis, and treatment options available for these diseases.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Current understanding and distinct features of multifocal and multicentric breast cancers

Avera,

Valentic,

Bui

2023

Cancer Reports

View full text Add to dashboard Cite

BackgroundMultifocal (MF) and multicentric (MC) breast cancers are referred to as synchronous, multiple ipsilateral breast cancers; however, the definitions vary among the literature, which has made understanding and analyzing these diseases challenging.Recent findingsThe incidence ranges from 1% to 60%, with a higher prevalence in pre‐menopausal women. MF and MC breast cancers, compared with unifocal breast cancers, tend to be more aggressive and are associated with lower survival rates, higher recurrence, and lymph node metastasis. Typically, patients with MF/MC breast cancers are treated with radical surgery, while breast conservation therapy may also be considered. Investigations have focused on elucidating the distinct biological features of MF/MC breast cancers, including the clonality of the cancers, the genetic alterations, and the impact of these features on disease aggressiveness and patient prognosis.ConclusionThese findings will broaden the understanding of these breast cancer subtypes and aid in the development of more tailored treatment plans for patients.

show abstract

Section: Heterogeneity Among Multiple Tumors In Multifocal/multicentr...mentioning

confidence: 99%

Section: Heterogeneity Among Multiple Tumors In Multifocal/multicentr...mentioning

confidence: 99%

Section: Heterogeneity Among Multiple Tumors In Multifocal/multicentr...mentioning

confidence: 99%

Section: Heterogeneity Among Multiple Tumors In Multifocal/multicentr...mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Current understanding and distinct features of multifocal and multicentric breast cancers

Avera,

Valentic,

Bui

2023

Cancer Reports

View full text Add to dashboard Cite

show abstract

Current Recommendations and Role of Breast Conservation Surgery for Multifocal or Multicentric Breast Cancer

Sabih

Lupinacci

Diego

2023

Curr Breast Cancer Rep

View full text Add to dashboard Cite

Evaluation of the impact of breast-conserving surgery on cancer outcomes of multiple (multifocal or multicentric) ipsilateral breast cancer

Abdelfattah,

Elzohery

2024

The Egyptian Journal of Surgery

View full text Add to dashboard Cite

Background Breast conservative therapy (BCT) includes conservative breast surgery (CBS) with adjuvant radiotherapy and is now considered a standard treatment for early-stage breast cancer to achieve survival with acceptable aesthetic outcomes. Management of multiple ipsilateral breast cancer (MIBC) is a challenge, since the choice of optimal surgical procedures is controversial. Recently, many breast surgeons have advocated CBS is technically feasible to safely excise MIBC in selected cases. Aim This study aimed to evaluate the outcome of MIBC patients who received CBS with special attention on local control and recurrence. Patient and method This retrospective study was carried out on 90 patients at Al Azhar University Hospital and Ain Shams University Hospitals between January 2021 and January 2023. Results The majority of patients 85 (94.4%) had two foci of disease while five (5.5%) patients had three foci. The distance between the lesions ranges between 0.5 and 6.5 cm. The most common type of CBS was wide local excision en bloc resection of all lesions with normal tissue in between was done in 85 (94.4%) patients and five (5.5%) patients had two separate incisions leaving normal tissue in between. Clear margins were reported in 79 (87.7%) patients. 15 (5.5%) patients had different pathological lesion types (heterogeneous). One patient had a recurrence and another had distant metastases. Conclusion With good patient selection, there is no difference between CBS and mastectomy in the management of MIBC. CBS is oncological safe provided that an adequate excision with clear margins followed by whole-breast radiation therapy and adjuvant systemic therapy.

show abstract

Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?

Cited by 3 publications

References 15 publications

Current understanding and distinct features of multifocal and multicentric breast cancers

Current understanding and distinct features of multifocal and multicentric breast cancers

Current Recommendations and Role of Breast Conservation Surgery for Multifocal or Multicentric Breast Cancer

Evaluation of the impact of breast-conserving surgery on cancer outcomes of multiple (multifocal or multicentric) ipsilateral breast cancer

Contact Info

Product

Resources

About